- Home
- BXSL vs ROIV Comparison
BXSL vs ROIV Comparison
Compare BXSL & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXSL
- ROIV
- Stock Information
- Founded
- BXSL 2018
- ROIV 2014
- Country
- BXSL United States
- ROIV United Kingdom
- Employees
- BXSL N/A
- ROIV N/A
- Industry
- BXSL Trusts Except Educational Religious and Charitable
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- BXSL Finance
- ROIV Health Care
- Exchange
- BXSL Nasdaq
- ROIV Nasdaq
- Market Cap
- BXSL 7.5B
- ROIV 8.4B
- IPO Year
- BXSL N/A
- ROIV N/A
- Fundamental
- Price
- BXSL $31.33
- ROIV $10.76
- Analyst Decision
- BXSL Buy
- ROIV Buy
- Analyst Count
- BXSL 6
- ROIV 4
- Target Price
- BXSL $31.38
- ROIV $17.50
- AVG Volume (30 Days)
- BXSL 988.2K
- ROIV 5.8M
- Earning Date
- BXSL 05-07-2025
- ROIV 05-29-2025
- Dividend Yield
- BXSL 9.85%
- ROIV N/A
- EPS Growth
- BXSL N/A
- ROIV N/A
- EPS
- BXSL 3.14
- ROIV N/A
- Revenue
- BXSL $1,380,706,000.00
- ROIV $122,585,000.00
- Revenue This Year
- BXSL $12.37
- ROIV N/A
- Revenue Next Year
- BXSL $8.12
- ROIV N/A
- P/E Ratio
- BXSL $9.97
- ROIV N/A
- Revenue Growth
- BXSL 16.76
- ROIV 140.04
- 52 Week Low
- BXSL $25.89
- ROIV $8.73
- 52 Week High
- BXSL $34.64
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- BXSL 62.57
- ROIV 49.48
- Support Level
- BXSL $29.07
- ROIV $10.58
- Resistance Level
- BXSL $30.04
- ROIV $11.77
- Average True Range (ATR)
- BXSL 0.51
- ROIV 0.34
- MACD
- BXSL 0.33
- ROIV -0.08
- Stochastic Oscillator
- BXSL 95.26
- ROIV 15.13
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.